- Home
- MPB vs MNMD Comparison
MPB vs MNMD Comparison
Compare MPB & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- MNMD
- Stock Information
- Founded
- MPB 1868
- MNMD 2019
- Country
- MPB United States
- MNMD United States
- Employees
- MPB N/A
- MNMD N/A
- Industry
- MPB Major Banks
- MNMD Pharmaceuticals and Biotechnology
- Sector
- MPB Finance
- MNMD Health Care
- Exchange
- MPB Nasdaq
- MNMD Nasdaq
- Market Cap
- MPB 628.8M
- MNMD 509.2M
- IPO Year
- MPB N/A
- MNMD N/A
- Fundamental
- Price
- MPB $28.13
- MNMD $9.61
- Analyst Decision
- MPB Buy
- MNMD Strong Buy
- Analyst Count
- MPB 2
- MNMD 7
- Target Price
- MPB $34.50
- MNMD $24.71
- AVG Volume (30 Days)
- MPB 122.8K
- MNMD 1.3M
- Earning Date
- MPB 07-23-2025
- MNMD 07-31-2025
- Dividend Yield
- MPB 2.84%
- MNMD N/A
- EPS Growth
- MPB N/A
- MNMD N/A
- EPS
- MPB 2.30
- MNMD N/A
- Revenue
- MPB $191,454,000.00
- MNMD N/A
- Revenue This Year
- MPB $24.31
- MNMD N/A
- Revenue Next Year
- MPB $13.74
- MNMD N/A
- P/E Ratio
- MPB $12.22
- MNMD N/A
- Revenue Growth
- MPB 13.34
- MNMD N/A
- 52 Week Low
- MPB $22.50
- MNMD $4.70
- 52 Week High
- MPB $33.87
- MNMD $10.49
- Technical
- Relative Strength Index (RSI)
- MPB 52.30
- MNMD 56.17
- Support Level
- MPB $27.10
- MNMD $7.96
- Resistance Level
- MPB $28.85
- MNMD $10.49
- Average True Range (ATR)
- MPB 0.54
- MNMD 0.55
- MACD
- MPB 0.14
- MNMD -0.06
- Stochastic Oscillator
- MPB 67.86
- MNMD 65.22
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).